Recent AGEN News
- Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference • Business Wire • 06/28/2024 03:10:00 PM
- Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies • Business Wire • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:01 PM
- Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors • Business Wire • 06/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:02:11 PM
- Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50 • Business Wire • 06/13/2024 09:15:00 AM
- Agenus Announces Virtual Annual Shareholders Meeting • Business Wire • 06/04/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:01:10 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/24/2024 09:00:00 PM
- Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting • Business Wire • 05/23/2024 09:10:00 PM
- Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 05/23/2024 11:30:00 AM
- FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer • Business Wire • 05/16/2024 11:30:00 AM
- Agenus Reports First Quarter 2024 Results • Business Wire • 05/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:39:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:38:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:31:13 AM
- Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement • Business Wire • 05/01/2024 11:30:00 AM
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting • Business Wire • 04/24/2024 02:00:00 PM
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update • Business Wire • 04/23/2024 11:30:00 AM
- Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer • Business Wire • 04/12/2024 11:30:00 AM
- Agenus Announces Reverse Stock Split of Common Stock • Business Wire • 04/05/2024 08:30:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM